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ABSTRACT: Diﬀuse large B-cell lymphoma (DLBCL) is the
most common B-cell non-Hodgkin lymphoma. To treat this
aggressive disease, R-CHOP, a combination of immunotherapy
(R; rituximab) and chemotherapy (CHOP; cyclophosphamide,
doxorubicin, vincristine, and prednisone), remains the most
commonly used regimen for newly diagnosed DLBCLs. However,
up to one-third of patients ultimately becomes refractory to initial
therapy or relapses after treatment, and the high mortality rate
highlights the urgent need for novel therapeutic approaches based
upon selective molecular targets. In order to understand the
molecular mechanisms underlying relapsed DLBCL, we studied
diﬀerences in the lipid and metabolic composition of nontreated
and R-CHOP-resistant tumors, using a combination of in vivo
DLBCL xenograft models and mass spectrometry imaging. Together, these techniques provide information regarding analyte
composition and molecular distributions of therapy-resistant and sensitive areas. We found speciﬁc lipid and metabolic proﬁles
for R-CHOP-resistant tumors, such as a higher presence of phosphatidylinositol and sphingomyelin fragments. In addition, we
investigated intratumor heterogeneity and identiﬁed speciﬁc lipid markers of viable and necrotic areas. Furthermore, we could
monitor metabolic changes and found reduced adenosine triphosphate and increased adenosine monophosphate in the R-
CHOP-resistant tumors. This work highlights the power of combining in vivo imaging and MSI to track molecular signatures in
DLBCL, which has potential application for other diseases.
Diﬀuse large B-cell lymphoma (DLBCL) is the mostcommon B-cell non-Hodgkin’s lymphoma (NHL)
throughout the world, comprising 30−35% of all NHLs, with
approximately 72 580 new cases and 20 150 deaths estimated
for 2016.1 Implemented 20 years ago, R-CHOP, a combination
of immunotherapy (R: rituximab, targeting the cell surface
protein CD20 expressed by B-cell lymphoma) and chemo-
therapy (CHOP: cyclophosphamide, doxorubicin, vincristine,
and prednisone), remains the most commonly used regimen
for newly diagnosed advanced DLBCLs. This therapy has
considerably improved treatment response,2−5 but DLBCL is a
biologically aggressive disease and up to one-third of patients
becomes refractory to initial therapy6 and displays a poor
survival outcome.7,8
The high mortality rate in patients with relapsed DLBCL
highlights the urgent need for novel therapeutic approaches
based upon selective molecular targets. Therefore, it is of high
importance to enhance our understanding of the various
mechanisms leading to tumor resistance/relapse in order to
develop eﬃcient therapies against refractory/relapsing
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DLBCL. To do so, two criteria are critical, (i) to precisely
monitor DLBCL cells’ response to R-CHOP treatment and
tumor progression, and (ii) to analyze global and local
molecular tumor proﬁles in relation to treatment response.
Implemented for the ﬁrst time two decades ago, live in vivo
bioluminescent imaging (BLI) has allowed researchers to
detect living cells in rodents in a noninvasive manner.9 Cells
are genetically modiﬁed in order to express a luciferase
enzyme, which, after injection of luciferin in the animal, will
lead to the emission of a luminescent signal. This signal is then
acquired and quantiﬁed by an in vivo imaging system (IVIS).
Of note, in cancer xenograft models, it also allows precise
monitoring and quantiﬁcation of tumor development from
earlier stages and more accurately than caliper measure-
ments.10 Moreover, in the past decade, scientists have
generated lentiviral vectors coupling ﬂuorescent markers and
luciferase, allowing for the stable generation of luminescent
variants of almost any cancer cell line.11 Such models have
been previously shown to eﬃciently monitor lymphoma cells
reaction to treatment in murine models.12
Mass spectrometry imaging (MSI) is an analytical tool
capable of identifying and mapping hundreds of molecules in a
single experiment from thin, biological sections. MSI diﬀers
from other imaging techniques as it is a label-free method used
to study molecules ranging from proteins and peptides13 to
lipids,14 metabolites,15 and drugs.16 MSI is commonly used to
study and characterize diﬀerent types of cancer.17,18
Matrix-assisted laser desorption/ionization (MALDI) is one
of the main ionization techniques used in the MSI ﬁeld. A thin
layer of matrix is deposited on-top of the sample in order to
help ionization and desorption of the molecules. Then, a laser
shoots across the tissue section recording the biomolecular
proﬁle (mass-to-charge ratio and relative intensity) of each
acquired position. Dedicated software allows the generation of
images at a given pair of x- and y-coordinates. MALDI-MSI19
oﬀers a very high spatial resolution (up to 1−5 μm)20,21 and an
acquisition speed of 50 pixels per second,22 providing
histological information at the biomolecular level.
Recent studies have demonstrated the advantages of
combining in vivo imaging and MSI in cancer research.
Indeed, Hinsenkamp et al. demonstrated the potential of the
ROCK1/2 inhibitor Fasudil in a gastric cancer model either by
positron emission tomography−computed tomography (PET/
CT) in vivo imaging or MALDI-MS imaging.23 Jiang et al. have
identiﬁed speciﬁc lipid proﬁles of hypoxic regions in a breast
cancer model by combining bioluminescence in vivo imaging
and MSI.24 In this work, we demonstrate the potential of using
BLI to follow the response to R-CHOP treatment and
MALDI-MSI to characterize the molecular proﬁles of resistant
tumors.
Our results reveal distinctive signatures of lipids and
metabolites in R-CHOP-resistant lymphoma tumors that
could help to identify new targets involved in treatment
resistance. Furthermore, our studies demonstrate that BLI−
MALDI-MSI combined can be applied to study molecular and
metabolic progression of many other diseases.
■ EXPERIMENTAL SECTION
The U2932 DLBCL cell line was obtained from American
Type Culture Collection, USA. A luminescent and ﬂuorescent
variant of the cell line was generated, on the basis of the
pFULT lentiviral system, as previously published (details in the
Supporting Information).24,25
Generation of DLBCL Xenografts. The 107 freshly
harvested U2932 pFULT cells (200 μL from a stock solution
of 5 × 107 cells/mL in PBS) were subcutaneously injected in
the right ﬂank of 40 NMRI-nude adult females (Janvier
Laboratories, France). Following injection, in vivo lumines-
cence imaging was used to follow tumor development using an
IVIS Lumina II (Caliper Life Sciences, USA). Mice were
checked daily to detect any sign of discomfort or sickness and
sacriﬁced by cervical dislocation if such condition would
appear. Of the 40 injected mice, 33 developed tumors and did
not present any side-eﬀects. Of these 33 tumorous mice, 5
were left untreated as controls, and 28 were treated with an R-
CHOP regiment once the tumor had reached a total
luminescence signal of at least 3 × 1010 photons/second.
One cycle of R-CHOP therapy was deﬁned as three
consecutive repeats of a weekly procedure, from indicated
time-points, based on published protocols.26,27 One procedure
consists of a single Rituximab (MabThera subcutaneous,
Roche, Switzerland) subcutaneous injection on day 1, dosed at
25 mg/kg combined with CHOP treatment as follows:
cyclophosphamide (Sigma-Aldrich, C0768, USA) intraperito-
neal (i.p.), day 2, dosed at 40 mg/kg; doxorubicin (Sigma-
Aldrich, D2975000, USA), i.p., day 2, dosed at 3.33 mg/kg;
vincristine (Sigma-Aldrich, V0400000, USA) i.p., day 2, dosed
at 0.2 mg/kg; and prednisone (Sigma-Aldrich, P6254, USA),
oral gavage from day 1 to 5 inclusive, dosed at 0.2 mg/kg. The
tumors were harvested and immediately heat-stabilized
(Stabilizor System, Denator, Sweden) in order to preserve
their molecular integrity before being snap-frozen in
isopentane and then stored at −80 °C until MSI analysis.
Mass Spectrometry Imaging. The 12 μm consecutive
sections were used in order to obtain technical triplicates of
each tumor and type of MSI experiment (lipids positive mode,
lipids negative mode, and metabolites).
Lipid Analysis. Prior to matrix application, the samples
were dried for 15 min. Norharmane (Sigma-Aldrich,
Gillingham, UK) matrix was applied to sections at 7 mg/mL
in 2:1 chloroform:methanol (v/v) using the TM-Sprayer M3
(HTX Technologies LLC, Carrboro, USA). Eleven layers were
applied with a drying time of 30 s between each layer using a
nozzle temperature of 30 °C with a ﬂow rate of 120 μL/min.
The velocity was set at 1200 mm/min combined with a track
passing of 3 mm allowing homogeneous matrix application.28
Metabolite Analysis. N-(1-Naphthyl) ethylenediamine
dihydrochloride (NEDC) (Sigma-Aldrich, Gillingham, UK)
matrix was applied to sections at 7 mg/mL in 70% methanol
(v/v). The spray parameters were the same as for the lipids
with the only diﬀerence that the nozzle temperature was set to
85 °C. 9-Aminoacridine hydrochloride monohydrate (9AA)
(Sigma-Aldrich, Gillingham UK) matrix was applied at 7 mg/
mL in 70% ethanol (v/v) using the SunCollect (SunChrom,
Friedrichsdorf, Germany). Twenty layers were applied with a
ﬂow rate of 40 μL/min and a Z oﬀset of 25 mm. The velocity
was set at 1250 mm/min combined with a line distance of 2
mm.
Lipids were detected using both positive and negative ion
polarities and metabolites only in the negative mode using a
Bruker RapiﬂeX MALDI Tissue-typer instrument operating in
reﬂectron mode (Bruker Daltonik GmbH, Germany) and an
Orbitrap Elite hybrid ion trap mass spectrometer (Thermo
Fisher Scientiﬁc, Bremen, Germany) (see the Supporting
Information).
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Imaging Processing. FlexImaging v4.1 (Bruker Daltonik
GmbH, Bremen, Germany) and SCiLS lab 2016b (SCiLS
GmbH, Bremen, Germany) were used to process the imaging
data acquired with the Bruker RapiﬂeX. Thermo Xcalibur
3.0.63 (Thermo Fisher Scientiﬁc, Bremen, Germany) was used
to analyze the Orbitrap imaging data. Principal component
analysis (PCA), hierarchical clustering analysis (HCA), and
linear discriminant analysis (LDA) were performed after peak
picking using an in-house-built ChemomeTricks toolbox for
MATLAB version 2014a (The MathWorks, Natick, USA).29
On-tissue pixels were selected as regions of interest (ROIs)
and assigned to a category representing the untreated and
resistant classes, respectively. PCA-LDA was performed with
one-fourth of the number of features as the number of
functions for the LDA,30 which were 337 functions for lipids in
negative polarity, 338 functions for lipids in positive polarity,
and 357 functions for metabolites. The scores that described
the diﬀerent discriminant functions (DF) were adjusted to
Gaussian curves following a normal distribution and projected
onto ROIs. DF is a variable that was composed to maximize
the variance between the groups and to minimize the variance
within the groups.
The lipids and metabolites were then identiﬁed using
tandem MS as well as the databases, LIPID MAPS Structure
Database (http://lipidmaps.org), ALEX123 lipid database
(http://alex123.info/ALEX123/MS.php),31 METLIN data-
base (https://metlin.scripps.edu), and Human Metabolome
Database (http://www.hmdb.ca/).
Figure 1. In vivo R-CHOP resistance of DLBCL cells monitored by in vivo imaging and classiﬁed by MSI. (A) Schematic of the experimental
design and workﬂow. (B) Overview of the mice used for this study. (C) Averaged tumoral development of the 5 untreated mice. Points and bars
are, respectively, mean ± SD at indicated time-points. (D) Tumoral development of R-CHOP-resistant mice. Stars indicate initiation of a R-CHOP
regimen, lasting 3 weeks. Final point for each mouse indicates tumor not responding to R-CHOP therapy anymore.
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After acquisition, the tissue sections were analyzed by
ﬂuorescent microscopy and stained for histological annotation.
For more details about material and methods, please see the
Supporting Information.
■ RESULTS AND DISCUSSION
In Vivo Imaging Monitoring To Follow the Tumor
Growth. We selected the U2932 DLBCL cell line to generate
our in vivo model (Figure 1A), as it presents a high expression
of v-myc avian myelocytomatosis viral oncogene homologue
(MYC) and B-cell lymphoma 2 (BCL2),32 a hallmark of
refractory/relapse DLBCL patients.33 Using the pFULT
lentiviral system, we generated a variant of this cell line stably
and constitutively expressing luciferase 2 as well as TdTomato
(Figure 1A). In a pilot experiment, we validated the possibility
of monitoring tumor development from these xenografts and
observed that tumors should reach a minimum total signal of 3
× 1010 photons/second before starting R-CHOP therapy in
order to obtain refractory/relapsing tumors (data not shown).
Then, we injected 40 mice, leading to 33 animals developing
tumors without presenting side-eﬀects; 5 control mice were
not treated (Figure 1B), presenting constant tumor growth
(Figures 1C and S1); and 28 were treated with the R-CHOP
regimen. As our aim was to characterize R-CHOP resistance,
we deﬁned resistant tumors as those presenting regular tumor
growth after serial regimens of R-CHOP treatment (Figure
1D). Under this criterion, 4 of the 28 injected, treated mice
showed R-CHOP-resistant tumors (Figures 1D and S1).
Diﬀerential Lipid Proﬁles between Untreated and
Relapsing Tumors Revealed by MALDI-MSI. Diﬀerent
lipid proﬁles between untreated and R-CHOP-resistant tumors
were revealed by MALDI-MSI (100 × 100 μm raster size).
Both ion polarities allowed for the visualization of diﬀerent
molecular classes. In negative-ion mode (Figure 2, Table 1),
we detected phosphatidylinositols (PI), phosphatidylethanol-
amines (PE), phosphatidylserines (PS), phosphatidylglycerols
(PG), and cardiolipins (CL). Principal component analysis
followed by linear discriminant analysis (PCA-LDA) was used
for data reduction and to look for speciﬁc proﬁles of each
condition (Figure 2A).
Figure 2. Discriminating untreated and R-CHOP-resistant tumors based on the lipid signature in negative polarity. (A) DF1 scaled loading
spectrum. (B) DF1 score projection. (C) Single peak intensity plots of PE 36:2 [M − H]− (left) and PE 18:0_22:5 [M − H]− (right).
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The DF1 of lipids in negative mode described 1.5% of the
total variance used for the LDA. The projection of the DF1
scores revealed diﬀerent biomolecular proﬁles for the untreated
and resistant tumors (Figure 2B). Of importance, diﬀerent
lipid families appeared to be speciﬁc to each condition (Table
1). PI and most PG species were speciﬁc of R-CHOP-resistant
tumors, whereas most PE and CL species were predominantly
detected in the untreated condition (Figure 2A,C). The higher
presence of PI in the relapsed condition is biologically relevant
as phosphoinositide 3-kinase, a key cellular signaling mediator
of this lipid family, which has been shown to be involved in
DLBCL pathogenesis by having a role in protein traﬃcking34
and is currently being investigated as a target for refractory/
relapsed DLBCL.35 Of note, we also observed some lipid
fragments from sphingomyelins (SM) d18:1_16:0 (m/z
687.54, [M − H]−), exclusively localized in certain tumor
regions.
In the positive-ion mode, diﬀerent lipid classes, such as
phosphocholines (PC), SM, and PE, were detected (Table 1).
The DF1 was discriminated between the two conditions
(Figure 3A,B), describing 1.1% of the total variance used for
the LDA. Likewise, individual lipids were more abundant in
one condition compared to the other (Table 1). For instance,
PC 34:2 (m/z 796.53, [M + K]+) was speciﬁc to the untreated
DLBCL, whereas PC O_38:4 (m/z 834.58, [M + K]+) was
more present in the resistant tumors (Figure 3A,C). Most of
the sodiated lipid adducts were detected in the resistant
condition. An interesting case is PC 36:2, predominantly
detected as m/z 786.60 [M + H]+ in untreated tumors and as
m/z 808.58 [M + Na]+ in the resistant condition (Table 1).
Other examples are SM (34:1:2) (m/z 725.56, [M + Na]+)
(Figure S3) and PC 38:4 (m/z 832.58, [M + Na]+), found to
be more present in the relapsed tumors. These observations
suggest that a higher content of Na+ would be involved in R-
CHOP resistance mechanisms. Chughtai et al.36 found that the
SM d18:1/16:0 sodium adduct primarily colocalized with
hypoxic and necrotic tumor regions, agreeing with Irigoyen et
al.37 who showed a correlation between hypoxia with the
aggressiveness, metastatic spread, and relapse of solid tumors.
Tumor Heterogeneity Characterized by MSI Lipido-
mic Proﬁles. Fluorescence microscopy experiments con-
ﬁrmed that all tumoral cells expressed TdTomato protein,
which was introduced in our DLBCL human cell line model
(Figures 1 and S2). This excluded the possibility of having
resected murine tissue with the tumor. Second, the H&E
stained slides were annotated by a pathologist, and we
identiﬁed these areas as necrotic regions (Figure S4A). MSI
of the treatment-resistant tumors (tumors 272 and 285)
distinguished between viable and necrotic regions, which were
similar to pathologist annotations in H&E-stained slides
(Figure S4). PCA was performed to evaluate speciﬁc lipid
proﬁles linked to these diﬀerent tumor areas (Figure S4B,C).
In order to further study tumor heterogeneity and identify
characteristic lipids of each area, we performed experiments at
a higher spatial (30 μm) and mass resolution (240 000
resolving power at m/z 400). In Figure 4, individual channels
were plotted to represent the speciﬁc lipid distribution in
viable and necrotic parts of resistant tumors. In the negative
mode, we were able to discriminate viable/necrotic areas, with
a higher presence of PI 18:0_20:4 (m/z 885.55, [M − H]−) in
the viable regions, while the SM d18:1_16:0 fragment (m/z
687.54, [M − H]−) was a marker for the dead cell state (Figure
4A). In the positive mode, we observed that PC 34:2 (m/z
796.53, [M + K]+) was a marker of the viable but R-CHOP-
resistant tumor tissue, whereas LPC 18:0 (m/z 524.37, [M +
H]+) was speciﬁc to the necrotic part (Figure 4B). This ﬁnding
conﬁrms previous studies that detected high PC levels in non-
necrotic tumor regions, revealing importance of PCs in the
following the tumor progression.38 In fact, Glunde et al.
described the importance of targeting choline metabolites for
early cancer detection.39
As mentioned above, most of the sodiated adducts were
assigned to the resistant condition. In addition, the distribution
of these sodiated species seemed to be speciﬁc to the necrotic
areas of resistant tumors; SM (34:1:2) (m/z 725.56, [M +
Na]+) (Figure S3), PC 36:2 (m/z 808.58, [M + Na]+), PC
32:0 (16:0/16:0) (m/z 756.55, [M + Na]+), and PC 38:4 (m/
z 832.58, [M + Na]+) are several examples. Our observations
are in agreement with those of Amstalden van Hove et al., who
also observed higher levels of Na+ in the necrotic tumor
regions by MSI.38 It is possible, that high Na+ levels lead to
necrosis, or that this high sodium presence could be a
consequence of the cell death process. These high sodium
levels may also correlate with a decrease in Na+/K+ pump
activity and an increase in cell permeability.34,36 Interestingly,
higher potassiated lipid species were found in viable compared
to necrotic tissue, such as PC 34:2 (m/z 796.53, [M + K]+).
This is supported as well by Summers et al., who showed that
Table 1. Lipid Assignments Based on MS/MS and High
Mass Resolution MSI Experiments
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higher K+ levels were found in viable tumor regions compared
to necrotic areas.40 Our results suggest that the presence of
sodiated lipids could indicate a good response to R-CHOP
therapy.
Metabolic Changes in Relapsed DLBCL Tumors. After
we optimized our method for MALDI-MSI detection of small
molecules using 9-AA and NEDC,41,42 we observed a higher
signal-to-noise ratio for metabolites, such as adenosine
monophosphate (AMP, m/z 346.06), adenosine diphosphate
(ADP, m/z 426.02), and adenosine triphosphate (ATP, m/z
505.99), using NEDC. In addition, the matrix peaks were less
abundant in the mass spectrum with NEDC compared to 9-
AA, which helped to avoid matrix interferences (Figure S5).
NEDC allowed the analysis of lipids and metabolites in a single
experiment. Hence, we performed analysis targeting metabo-
lites using NEDC at a raster size of 100 μm.
PCA-LDA showed a separation between the untreated and
resistant tumors (Figure 5A). The DF1 described 2.0% of the
total variance used for the LDA. The DF1 score projections
looked similar for all triplicates and molecular classes (Figure
S6). In addition, we identiﬁed metabolites that discriminated
untreated from R-CHOP resistant tumors (Figure 5B). As an
example, ATP was more abundant in the untreated sections
(Figure 5C), whereas AMP presented a relatively higher
intensity in the viable areas of the R-CHOP-resistant tumors
(Figure S7). Previous studies reported that ATP consumption
serves to increase glucose ﬂux to satisfy the energetic and
biosynthetic demands of a rapidly proliferating cancer cell.43
ATP production is associated with CLs via the electron
transport chain, which is involved in oxidative phosphor-
ylation,42,43 a more eﬃcient pathway for ATP production than
glycolysis.44 We found that most of the CL species were more
abundant in the untreated samples, as shown in the DF
spectrum of the lipids in negative mode (Figure 2A). CLs are a
class of mitochondrion-speciﬁc anionic phospholipids and play
multiple structural and functional roles in bioenergetics.
According to Kiebish et al., environmental factors, including
necrosis and hypoxia, could alter CL content and/or
composition, which could aﬀect tumor initiation or pro-
gression.45 Importantly, CHOP has been suggested to
inﬂuence metabolism and the mitochondrial state in
lymphoma xenografts in vivo.46,47 Indeed, diﬀerences in
Figure 3. Discriminating untreated and R-CHOP-resistant tumors based on the lipid signature in positive polarity. (A) DF1 scaled loading
spectrum. (B) DF1 score projection. (C) Single peak intensity plots of PC 34:2 [M + K]+ (left) and PC O_38:4 [M + K]+ (right).
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metabolism and mitochondrial state have been characterized in
lymphoma patients.38,39
Regarding glycerophosphocholine, we observed that this
major form of choline storage (shown as dysregulated in
cancer metabolism38,48,49 by others) was speciﬁc to resistant
tumors. Interestingly, glycerophosphocholine has been asso-
ciated with poor prognosis in breast cancer.50 Our ﬁndings
suggest that the highest level of glycerophosphocholine present
in the resistant tumors could be linked to PCs, which were also
more abundant in the resistant tissues. Other groups have
described a relationship between diﬀerential biomolecular
proﬁles and cell density, which might be related to a higher cell
division rate in aggressive tumors.51,52
■ CONCLUSION
Our approach shows the potential of combining in vivo
imaging and MSI to investigate molecular diﬀerences
associated with successful and nonresponsive cancer treatment.
To our knowledge, our study is the ﬁrst that combines
bioluminescence in vivo imaging, for characterization of lipids
Figure 4. Intratumor heterogeneity. (A) Negative-ion mode images show the spatial distribution of PI 18:0_20:4 (left) and SM d18:1_16:0
(middle) in viable and necrotic regions, respectively, determined by H&E staining (right). (B) Positive-ion mode images show the spatial
distribution of PC 34:2 (left) and LPC 18:0 (middle), which correlated to viable and necrotic areas, respectively, again determined by H&E
staining (right).
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and metabolic proﬁles associated with R-CHOP resistant
tumors. Moreover, speciﬁc molecular signatures could be
associated with intratumor heterogeneity. MSI is a robust tool
to discover new markers and signatures of lymphoma, which
could be applied to investigate other cancers and their speciﬁc
treatment success/resistance.
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